Overview

A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter

Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Cardiome Pharma
Correvio International Sarl
Collaborator:
Astellas Pharma US, Inc.